Details of the Drug

General Information of Drug (ID: DM7J5H0)

Drug Name
SAR444200
Indication
Disease Entry ICD 11 Status REF
Aggressive cancer 2A00-2F9Z Phase 2 [1]
Drug Type
Nanobody
Cross-matching ID
TTD ID
DF6Z3C

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glypican-3 (GPC3) TTJTSX4 GPC3_HUMAN Not Available [2]
T-cell receptor (TCR) TT7AKW1 NOUNIPROTAC Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Aggressive cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Glypican-3 (GPC3) DTT GPC3 5.54E-86 3 9.74
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05450562) A Phase 1/2 Open-label, First-in-human, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR444200-based Regimen in Participants With Advanced Solid Tumors. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Sanofi